zintick

Dexcom DXCM

Dexcom Inc · Nasdaq · Surgical & Medical Instruments & Apparatus

$78.62+0.08%close on Oct. 28, 2026 · volume 5.4M · Yahoo Finance

Price, last 47 sessions

$80.00$85.00$90.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $91.06 · low $77.94 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 27, 2026Sadie Stern
EVP Chief People & Culture Off
Sold
10b5-1 plan
2,565$78.62$201,660
Oct. 15, 2026Michael Jon Brown
EVP Chief Legal Compliance Off
Sold
10b5-1 plan
1,700$85.48$145,316
Sept. 28, 2026Sadie Stern
EVP Chief People & Culture Off
Sold
10b5-1 plan
2,565$86.15$220,975
Sept. 15, 2026Nicholas Augustinos
director · indirect
Sold
10b5-1 plan
6,539$84.04$549,538
Sept. 15, 2026Michael Jon Brown
EVP Chief Legal Compliance Off
Sold
10b5-1 plan
1,700$84.04$142,868
Sept. 14, 2026Nicholas Augustinos
director · indirect
Sold
10b5-1 plan
1,550$84.02$130,231
Sept. 10, 2026Jereme M. Sylvain
EVP, Chief Financal Officer
Sold
10b5-1 plan
3,638$83.27$302,936
Aug. 27, 2026Sadie Stern
EVP Chief People & Culture Off
Sold
10b5-1 plan
2,565$88.37$226,669
Aug. 20, 2026Kevin R. Sayer
Executive Chair, director
Sold
10b5-1 plan
26,756$90.01
$89.71-$91.41
$2.41 million
Aug. 14, 2026Michael Jon Brown
EVP Chief Legal Compliance Off
Sold
10b5-1 plan
1,700$91.93$156,281
Aug. 12, 2026Bridgette P. Heller
director
Sold
10b5-1 plan
1,012$88.29$89,349
Aug. 3, 2026Mark G. Foletta
director · indirect
Sold
10b5-1 plan
2,000$85.32$170,640

Latest 12 of 13. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 21 →